Andrea Carafa

Andrea Carafa

Auto-generated profile, based on publicly available information

Andrea Carafa

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
Renata RisiRenata Risi
Renata Risi
DPDomiziana Pauletto
Domiziana Pauletto
VBValeria Zanghi Buffi
Valeria Zanghi Buffi
VBValentina Berna
Valentina Berna
ACAndrea Carafa
Andrea Carafa
TGthe AD_OWOB study group
the AD_OWOB study group
Background: Type 1 diabetes (T1D) and overweight/obesity (OW) are chronic conditions impairing health‐related quality of life (HRQoL). While diabetes primarily affects psychosocial domains, OW impacts physical functioning and social stigma. Despite the increasing prevalence of OW among individuals with T1D, their combined effect on HRQoL has not been investigated. Methods: In this cross‐sectional, multicentre study we evaluated HRQoL in 43 people with both T1D and OW (T1DOW), 40 people with T1D normal weight (T1DNW), 58 normal weight people without diabetes (NADNW) and 41 people with OW without diabetes (NADOW). All participants completed generic HRQoL questionnaires (WHO‐5, SF‐36). People with T1D additionally completed diabetes‐specific tools (DDS, DES‐SF and T1‐DDAS). Adjusted multivariate analyses were used to evaluate the independent and interactive effects of T1D and OW on HRQoL. Results: T1D was associated with reduced well‐being (WHO‐5, p = 0.003), impaired general health perception (SF‐36, p < 0.001) and lower social functioning (SF‐36, p = 0.026). OW significantly worsened physical functioning ( p < 0.001) and role limitations due to physical health ( p = 0.036). Bodily pain was synergistically affected by both T1D ( p = 0.043) and OW ( p = 0.006), with people affected by both T1D and OW showing the worst score. Overall, T1DOW was associated with greater detrimental effects on WHO‐5 and SF‐36 outcomes compared to OW and T1D alone. Among people with T1D, OW selectively increased interpersonal distress (DDS, p = 0.020), while empowerment and T1D‐specific distress were unaffected. Conclusions: T1D and OW exert distinct, partially overlapping effects on HRQoL. Their coexistence worsens body pain and interpersonal distress and emphasises the need for integrated strategies in managing ‘double diabetes’.

1 December 2025 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
ACAndrea Carafa
Andrea Carafa
EMErnesto Maddaloni
Ernesto Maddaloni

21 September 2026 in Acta Diabetologica
Verified
Journal Article
Open access
PDF file
ACAndrea Carafa
Andrea Carafa
RSRosario Luigi Sessa
Rosario Luigi Sessa
RARocco Amendolara
Rocco Amendolara
SZSimona Zampetti
Simona Zampetti
CMCarmen Mignogna
Carmen Mignogna
RBRaffaella Buzzetti
Raffaella Buzzetti
Context: The phenotypic drift of circulating monocytes toward osteoblast-like cells expressing osteocalcin (OCN) has been linked to vascular calcification in individuals with type 2 diabetes (T2D). The synergistic action of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and metformin may reduce the cardiovascular risk by modulating OCN-expressing monocytes, representing a novel mechanism of cardiovascular protection. Objective: To investigate the impact of GLP-1 RA add-on metformin therapy on the percentage of circulating CD14 + OCN + monocytes. Research design and methods: This longitudinal study enrolled patients with T2D receiving metformin monotherapy who either initiated GLP-1 RA therapy (Group A, n = 7) or did not (Group B, n = 28). Clinical parameters and circulating CD14+OCN+ cell levels were assessed at baseline (V0), after 1 week (V1) and after 12 weeks (V2). In vitro experiments were conducted using peripheral blood mononuclear cells (PBMCs) from healthy volunteers (n = 10), treated with metformin or exendin-4 for 24 h. Results: In group A, the percentage of CD14+OCN+ significantly decreased from baseline (4.5 [2.5–7.6]) to V2 (2.2 [1.73–4.9]% p = 0.019). This reduction was already significant at V1 (p = 0.039). No significant change over time was observed in Group B (p = 0.31). In vitro treatment of PBMCs with metformin significantly reduced the percentage of CD14 + OCN + cell (− 34.9%, p < 0.0001), whereas exendin-4 yielded a non-significant downward trend (− 8.5%, p = 0.1). Conclusion: GLP-1 RA add-on therapy to metformin reduces OCN expression in circulating monocytes in patients with T2D. In vitro data suggest that this effect might not result from a direct effect on mononuclear cells, but rather from indirect systemic mechanisms that warrant further investigation. These findings identify OCN-expressing monocytes as a potential novel therapeutic target for GLP-1 RA to reduce cardiovascular risk in T2D.